KTT is applied to all innovative research that has potential for further technological development and exploitation. These types of research projects need to be identified early in order for the intellectual property to be protected by patents, copyrights or licensing agreements.

In 2017,  Synapsy researchers made five invention announcements and created a start-up biotech company (GliaPharm).